ProtocolsPerformance & enduranceEndurance
← Protocols

Endurance

Stack: BPC-157 + TB-500 + NAD⁺ / NMN · WADA-aware
"A recovery pattern for endurance loads. No endurance-specific human data exists — the rationale is general recovery, and athletes should check WADA status themselves."
GoalEndurance recovery
Compounds3 · BPC-157 + TB-500 + NAD⁺ / NMN
Humans exposed (est.)Moderate — undocumented
StatusMHRA (UK): not licensed medicines here · FDA (US): BPC-157/TB-500 status evolving · WADA: check current prohibited list
In this stack — snapshot; tap through for the full molecule file
Provenance & evidence layers — of the combination, not the parts
Where / who
Community / athlete and clinic use as tagged above.
Use status
Used in endurance circles for recovery.
Evidence it adds
Popularity / convention — not efficacy.
Basis: real-world uptake & convention — not trial data
Where / who
US functional-medicine, longevity & sports-medicine clinics — physician-prescribed via 503A/503B compounding pharmacies.
Track record
BPC-157 / TB-500: among the most commonly compounded peptides in US clinics until the Sept 2023 FDA Category 2 listing disrupted legitimate compounding — see the regulatory layer for current status.
Evidence it adds
Real-world clinical observation — physician-charted, supervised use. A genuine evidence tier, but observational: uncontrolled, unpublished, no registry, outside formal pharmacovigilance.
What it means
Off-label compounding under prescription — never an FDA-approved therapy. Removal from Category 2 is not approval.
Basis: US compounding-pharmacy practice · FDA Docket FDA-2025-N-6895
Clinical record
No country lists this exact combination as an approved therapy.
Human trials
No completed human trial of the combination. No endurance-specific human data.
Basis required for a clinical-use tag: none found — absence shown, not hidden
FDA (US)
BPC-157 / TB-500 were FDA Category 2 (compounding prohibited) 2023–Apr 2026; removed Apr 2026, under PCAC review (23–24 Jul 2026).
MHRA (UK)
Not licensed medicines. Sold as research material.
What it means
Removal from Category 2 is not approval — the compounding decision is pending.
Why it matters
No marketing authorisation = no pharmacovigilance; adverse events aren't formally tracked.
Basis: FDA Docket FDA-2025-N-6895 · PCAC 23–24 Jul 2026 — updates after the decision
Why this combination

The healing pair plus NAD⁺ for cellular energy. There is no endurance-specific human evidence — the case is general recovery pharmacology. Competitive athletes must verify current WADA status independently.

Members only · the actionable depth
See exactly how it's run
Doses, cycle structure and what to monitor are part of membership. The provenance, evidence and exposure above are always free.
Get TiQ1 · Free →
Free · just create an account
Cycle shape — how it's typically structured, not a schedule to follow
Loading
build up
Maintenance
hold / taper
Off
stop / reassess
Convention from community use, not a prescription.
What's worth monitoring

With limited or no human safety data for this combination, there is no established marker set to monitor against — which is a reason for more caution, not less. Baseline bloods and a clinician conversation matter here. General information, not medical advice.